Prot # GS-US-337-0102: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavarin for 12 and 24 Weeks in Treatment-Naive Subjects with Chronic Genotype 1 HCV Infecti

Project: Research project

Project Details

Effective start/end date10/5/1210/5/15


  • PRA Health Sciences (Prot # GS-US-337-0102)
  • Gilead Sciences, Inc. (Prot # GS-US-337-0102)